CN107922428B - 噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途 - Google Patents

噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途 Download PDF

Info

Publication number
CN107922428B
CN107922428B CN201680044238.1A CN201680044238A CN107922428B CN 107922428 B CN107922428 B CN 107922428B CN 201680044238 A CN201680044238 A CN 201680044238A CN 107922428 B CN107922428 B CN 107922428B
Authority
CN
China
Prior art keywords
ethyl
amino
oxoethyl
thieno
pyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680044238.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922428A (zh
Inventor
S·迪尤尔曼
M·B·罗贝斯
J·R·沃克
W·周
C·齐姆普里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promega Corp
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of CN107922428A publication Critical patent/CN107922428A/zh
Application granted granted Critical
Publication of CN107922428B publication Critical patent/CN107922428B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
CN201680044238.1A 2015-06-25 2016-06-24 噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途 Active CN107922428B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562184714P 2015-06-25 2015-06-25
US62/184,714 2015-06-25
US201562206525P 2015-08-18 2015-08-18
US62/206,525 2015-08-18
PCT/US2016/039307 WO2016210294A1 (en) 2015-06-25 2016-06-24 Thienopyrrole compounds and uses thereof as inhibitors of oplophorus-derived luciferases

Publications (2)

Publication Number Publication Date
CN107922428A CN107922428A (zh) 2018-04-17
CN107922428B true CN107922428B (zh) 2021-02-05

Family

ID=56373143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680044238.1A Active CN107922428B (zh) 2015-06-25 2016-06-24 噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途

Country Status (6)

Country Link
US (2) US10513694B2 (https=)
EP (1) EP3313846B1 (https=)
JP (1) JP6862368B2 (https=)
CN (1) CN107922428B (https=)
ES (1) ES2809208T3 (https=)
WO (1) WO2016210294A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210294A1 (en) 2015-06-25 2016-12-29 Promega Corporation Thienopyrrole compounds and uses thereof as inhibitors of oplophorus-derived luciferases
EP3548492B1 (en) 2016-12-01 2023-07-05 Promega Corporation Cell impermeable coelenterazine analogues
WO2018125992A1 (en) * 2016-12-28 2018-07-05 Promega Corporation Functionalized nanoluc inhibitors
US11327072B2 (en) 2017-02-09 2022-05-10 Promega Corporation Analyte detection immunoassay
JP7419260B2 (ja) 2018-05-01 2024-01-22 プロメガ コーポレイション ＮａｎｏＬｕｃ自殺基質としてのセレンテラジン化合物
EP3802514B1 (en) * 2018-06-01 2022-08-03 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
WO2020041579A1 (en) 2018-08-23 2020-02-27 Promega Corporation Coelenterazine analogues
WO2020135771A1 (zh) 2018-12-29 2020-07-02 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用
KR20250085812A (ko) 2022-10-14 2025-06-12 프로메가 코포레이션 코엘렌테라진 유사체
US20250206747A1 (en) 2023-12-20 2025-06-26 Promega Corporation Coelenterazine analogues

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981975A (en) * 1988-08-23 1991-01-01 Basf Aktiengesellschaft Benzimidazole-2-carboxanilides
WO1993020099A3 (en) * 1992-03-27 1993-11-25 Ferring Bv Cck and/or gastrin receptor ligands
US5340801A (en) * 1991-05-08 1994-08-23 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having cholecystokinin and gastrin antagonistic properties
WO2003044014A1 (en) * 2001-11-22 2003-05-30 Aventis Pharma Deutschland Gmbh Indole-2-carboxamides as factor xa inhibitors
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
WO2006055951A2 (en) * 2004-11-19 2006-05-26 Portola Pharmaceuticals, Inc. Tetrahydroisoquinolines as factor xa inhibitors
WO2007054453A2 (en) * 2005-11-11 2007-05-18 F. Hoffmann-La Roche Ag Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
WO2007088277A1 (fr) * 2006-02-03 2007-08-09 Sanofi-Aventis Dérivés de ν-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur préparation et leur application en thérapeutique
WO2008118445A1 (en) * 2007-03-26 2008-10-02 Promega Corporation Methods to quench light from optical reactions
WO2009000878A1 (en) * 2007-06-28 2008-12-31 Novartis Ag Kallikrein 7 modulators
WO2010118208A1 (en) * 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283179A (en) * 1990-09-10 1994-02-01 Promega Corporation Luciferase assay method
US7268229B2 (en) 2001-11-02 2007-09-11 Promega Corporation Compounds to co-localize luminophores with luminescent proteins
US8163910B2 (en) 2007-10-03 2012-04-24 Elitech Holding B.V. Amide-substituted xanthene dyes
ES2795287T3 (es) 2009-05-01 2020-11-23 Promega Corp Luciferasas de Oplophorus sintéticas con mayor emisión de luz
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
CN103180324A (zh) 2010-11-02 2013-06-26 普罗美加公司 腔肠素衍生物及其使用方法
SG10202103336SA (en) 2010-11-02 2021-04-29 Promega Corp Novel coelenterazine substrates and methods of use
JP6067019B2 (ja) 2011-09-02 2017-01-25 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 代謝的に活性な細胞の酸化還元状態を評価するための化合物及び方法、ならびにｎａｄ（ｐ）／ｎａｄ（ｐ）ｈを測定するための方法
US20140099654A1 (en) * 2012-09-26 2014-04-10 Promega Corporation Real-time monitoring
WO2015067302A1 (en) 2013-11-05 2015-05-14 Ecole Polytechnique Federale De Lausanne (Epfl) Sensor molecules and uses thereof
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
EP3099691B1 (en) 2014-01-29 2019-11-20 Promega Corporation Pro-substrates for live cell applications
EP3304078B1 (en) 2015-06-05 2022-08-31 Promega Corporation Cell-permeable, cell-compatible, and cleavable linkers for covalent tethering of functional elements
WO2016210294A1 (en) 2015-06-25 2016-12-29 Promega Corporation Thienopyrrole compounds and uses thereof as inhibitors of oplophorus-derived luciferases
WO2018125992A1 (en) 2016-12-28 2018-07-05 Promega Corporation Functionalized nanoluc inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981975A (en) * 1988-08-23 1991-01-01 Basf Aktiengesellschaft Benzimidazole-2-carboxanilides
US5340801A (en) * 1991-05-08 1994-08-23 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having cholecystokinin and gastrin antagonistic properties
WO1993020099A3 (en) * 1992-03-27 1993-11-25 Ferring Bv Cck and/or gastrin receptor ligands
WO2003044014A1 (en) * 2001-11-22 2003-05-30 Aventis Pharma Deutschland Gmbh Indole-2-carboxamides as factor xa inhibitors
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
WO2006055951A2 (en) * 2004-11-19 2006-05-26 Portola Pharmaceuticals, Inc. Tetrahydroisoquinolines as factor xa inhibitors
WO2007054453A2 (en) * 2005-11-11 2007-05-18 F. Hoffmann-La Roche Ag Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
WO2007088277A1 (fr) * 2006-02-03 2007-08-09 Sanofi-Aventis Dérivés de ν-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur préparation et leur application en thérapeutique
WO2008118445A1 (en) * 2007-03-26 2008-10-02 Promega Corporation Methods to quench light from optical reactions
WO2009000878A1 (en) * 2007-06-28 2008-12-31 Novartis Ag Kallikrein 7 modulators
WO2010118208A1 (en) * 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Fragment Deconstruction of Small, Potent Factor Xa Inhibitors: Exploring the Superadditivity Energetics of Fragment Linking in Protein–Ligand Complexes";Marc Nazar et al.;《Angew. Chem. Int. Ed.》;20111211;第51卷;第906页表1 *
STN Registry数据库;美国化学会;《美国化学会》;20130612;第1-7页 *

Also Published As

Publication number Publication date
WO2016210294A1 (en) 2016-12-29
ES2809208T3 (es) 2021-03-03
JP2018524334A (ja) 2018-08-30
JP6862368B2 (ja) 2021-04-21
EP3313846B1 (en) 2020-05-06
EP3313846A1 (en) 2018-05-02
CN107922428A (zh) 2018-04-17
US20200063110A1 (en) 2020-02-27
US10513694B2 (en) 2019-12-24
US20160376568A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
CN107922428B (zh) 噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途
JP7161475B2 (ja) 官能化ｎａｎｏｌｕｃ阻害剤
JP5391264B2 (ja) １−ヘテロシクリル−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びそれらのｐｄｅ９ａモジュレーターとしての使用
JP2024156841A (ja) 二環式ペプチドリガンドおよびその使用
KR20170042591A (ko) Trk 저해 화합물의 산부가염
JP2022526926A (ja) イミダゾロニルキノリン化合物およびそれらの治療への使用
JP6805172B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
KR20120003868A (ko) １―헤테로사이클릴―１,５―디하이드로―피라졸로［３,４―ｄ］피리미딘―４―온 유도체 및 ｐｄｅ９ａ 조절인자로서의 이의 용도
CN103459397A (zh) 6-环丁基-1,5-二氢-吡唑并[3,4-d]嘧啶-4-酮衍生物及其作为PDE9A抑制剂的用途
EP3099691A1 (en) Pro-substrates for live cell applications
CN110494433A (zh) 布鲁顿酪氨酸激酶抑制剂
JP2023178294A (ja) Ｏｐｌｏｐｈｏｒｕｓルシフェラーゼ由来生物発光性複合体の阻害剤
WO2019213119A1 (en) Coelenterazine compounds as nanoluc suicide substrates
CN117836270A (zh) Usp30抑制剂及其用途
JP7200102B2 (ja) エネルギー受容体に係留されたセレンテラジン類縁体
JP2019514899A (ja) 共有結合型ｂｔｋ阻害剤及びその使用
TW202334132A (zh) Ｓａｒｍ１酶活性抑制劑及其應用
JP6457523B2 (ja) 医薬組成物のためのスルホキシイミン置換キナゾリン
KR20090007391A (ko) 키나제 억제제로서의 ３-비치환된 Ｎ-(아릴- 또는 헤테로아릴)-피라졸로[１,５-ａ]피리미딘
US20220274997A1 (en) Pim kinase inhibitor compositions and uses thereof
RU2779497C2 (ru) Макроцикл, содержащий аминопиразол и пиримидин, и его фармацевтическая композиция и применение
WO2025151850A9 (en) Spirocycle acrylamides that stereo- and site-selectively degrade the transcriptional and dna-damage response protein ercc3
HK40106156A (zh) Usp30抑制剂及其用途
HK40002681B (zh) 八氢稠合的氮杂萘烷糖皮质激素受体调节剂
HK1262884A1 (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant